These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16122403)

  • 21. Inhaled respiratory medications and the use of chlorofluorocarbons (CFCs). Thoracic Society of Australia and New Zealand.
    Pierce RJ; Seale JP; Ruffin RE
    Med J Aust; 1991 May; 154(10):701-4. PubMed ID: 2034155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing aerosol delivery by pressurized metered-dose inhalers.
    Rubin BK; Fink JB
    Respir Care; 2005 Sep; 50(9):1191-200. PubMed ID: 16122402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think?
    Hartung TK; Allbutt H; Dewar M; Innes JA; Crompton GK
    Respiration; 2002; 69(4):314-9. PubMed ID: 12169743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure.
    Emmen HH; Hoogendijk EM; Klöpping-Ketelaars WA; Muijser H; Duistermaat E; Ravensberg JC; Alexander DJ; Borkhataria D; Rusch GM; Schmit B
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):22-35. PubMed ID: 11029265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability.
    Brindley A
    J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition to CFC-free metered dose inhalers--into the new millennium.
    McDonald KJ; Martin GP
    Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Problems raised by the reformulation of inhalations after the removing of propulsors "chlorofluorocarbons" (CFC)].
    Aiache JM
    Ann Pharm Fr; 1997; 55(2):62-8. PubMed ID: 9181702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CFC Phase-Out and the Chiesi Solution.
    Huchon G; Fabbri LM
    Respiration; 2005; 72 Suppl 1():1-2. PubMed ID: 15915005
    [No Abstract]   [Full Text] [Related]  

  • 29. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rejuvenated pressurised metered dose inhaler.
    Bell J; Newman S
    Expert Opin Drug Deliv; 2007 May; 4(3):215-34. PubMed ID: 17489650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The challenge of reformulation.
    Smith IJ
    J Aerosol Med; 1995; 8 Suppl 1():S19-27. PubMed ID: 10150491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydrofluoroalkane preparations of fluticasone propionate.
    McCallister JW; Moore WC
    Expert Rev Respir Med; 2008 Aug; 2(4):433-42. PubMed ID: 20477207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albuterol inhalers.
    Gross NJ
    N Engl J Med; 2007 Jun; 356(26):2749; author reply 2749. PubMed ID: 17596614
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel pMDI formulations for pulmonary delivery of proteins.
    Li HY; Seville PC
    Int J Pharm; 2010 Jan; 385(1-2):73-8. PubMed ID: 19854252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The president speaks: prevention is best: lessons from protecting the ozone layer.
    Woodcock A
    Thorax; 2012 Dec; 67(12):1028-31. PubMed ID: 23019254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel formulation technique for metered dose inhaler (MDI) suspensions.
    Steckel H; Wehle S
    Int J Pharm; 2004 Oct; 284(1-2):75-82. PubMed ID: 15454299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ozone layer and metered dose inhalers.
    Boulet LP
    Can Respir J; 1998; 5(3):176-9. PubMed ID: 9707462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of two methods to determine the solubility of compounds in aerosol propellants.
    Gupta A; Myrdal PB
    Int J Pharm; 2005 Mar; 292(1-2):201-9. PubMed ID: 15725567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metered dose inhalers and spacer devices.
    Terzano C
    Eur Rev Med Pharmacol Sci; 1999; 3(4):159-69. PubMed ID: 11073122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
    Hoe S; Young PM; Rogueda P; Traini D
    AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.